Patents by Inventor Michael W. Flanagan

Michael W. Flanagan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9260471
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: February 16, 2016
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Mark Cancilla, James J. Cunningham, Michael W. Flanagan, Henry J. Haringsma, Denise Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron Willingham
  • Publication number: 20130217756
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Application
    Filed: October 25, 2011
    Publication date: August 22, 2013
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Mark Cancilla, James John Cunningham, Michael W. Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham